Trial abstract · §3
REDEFINE-4 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Percentage change in body weight, cagrilintide with semaglutide versus tirzepatide | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for CagriSema (cagrilintide with semaglutide) from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | — | — | Combination gastrointestinal burden is broadly the sum of the component profiles rather than additive beyond it |
| Vomiting | — | — | Reported at higher incidence than semaglutide monotherapy in cross-trial comparison, which the Institute notes is not a randomised comparison |
| Discontinuation for adverse events | 6.0 | 3.0 | REDEFINE 1 (approximate) |
Compound Evidence Institute · CEI-TR-0051/3 · https://compoundevidence.com/trials/redefine-4/results/ · retrieved 30 July 2026